Skip to main
GH

GH Stock Forecast & Price Target

GH Analyst Ratings

Based on 20 analyst ratings
Buy
Strong Buy 40%
Buy 55%
Hold 5%
Sell 0%
Strong Sell 0%

Bulls say

Guardant Health has demonstrated robust financial performance, with a year-over-year revenue growth of 7% despite challenging comparisons, positioning the company favorably in the liquid biopsy market. With over 50% market share in comprehensive genomic profiling and a projected increase in test frequency, particularly with the Reveal MRD test, Guardant is well-positioned for significant long-term growth. Additionally, the recent attainment of reimbursement coverage for its Reveal and Shield tests is expected to enhance average selling prices and drive volume growth, further strengthening the company's financial outlook.

Bears say

Guardant Health's stock outlook appears negative due to the potential for decreasing reimbursement, which could adversely affect average selling prices and overall revenues. The company's reliance on favorable reimbursement dynamics is further underscored by the pending PAMA regulations that could lead to a significant one-time revenue decline of approximately $100 million. Additionally, uncertainties in the regulatory landscape for multi-cancer early detection (MCED) tests pose risks to achieving necessary reimbursements, potentially hindering market adoption of Guardant's assays.

GH has been analyzed by 20 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 55% recommend Buy, 5% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Guardant Health Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Guardant Health Inc (GH) Forecast

Analysts have given GH a Buy based on their latest research and market trends.

According to 20 analysts, GH has a Buy consensus rating as of Apr 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $116.80, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $116.80, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Guardant Health Inc (GH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.